FOLIVANE-F- ferrous fumarate, iron, folic acid, ascorbic acid, and niacin capsule 
Trigen Laboratories, LLC

----------

Folivane™-F
with Ascorbic Acid Precursors

SUPPLEMENT FACTS

Rev072018B

Folivane™-F is a professionally prescribed iron, folic acid, and vitamin supplement used to improve the nutritional status of patients with iron and/or folate deficiency anemia, including women in the prenatal and postnatal period. Do not administer to children under the age of 12.

CONTRAINDICATIONS

Folivane™-F is contraindicated in patients with a known hypersensitivity to any of the ingredients, also, all iron compounds are contraindicated in patients with hemosiderosis, hemochromatosis, or hemolytic anemias. Pernicious anemia is a contraindication, as folic acid may obscure its signs and symptoms.

WARNINGS

 WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.

PRECAUTIONS

General: Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where B12 is deficient. Anemia requires appropriate investigation to determine its cause or causes. Periodic clinical and laboratory studies are considered essential. Blood tests including hemoglobin and hematocrit should be done to determine the adequacy of therapy. Folic acid should be used with care in the presence of peptic ulcer disease, regional enteritis, and ulcerative colitis. In doses above 0.1 mg daily, folic acid may obscure the diagnosis of pernicious anemia.

USAGE IN PREGNANCY
Before Folivane™-F is prescribed for megaloblastic anemia in pregnancy, appropriate diagnostic exclusion of Addisonian pernicious anemia (due to faulty or blocked absorption of vitamin B12, or extrinsic factor or either a genetic, immunological or surgical basis) should be carried out.

Pediatric Use: Safety and effectiveness of this product have not been established in pediatric patients.

Geriatric Use: Safety and effectiveness of this product have not been established in elderly patients.

ADVERSE REACTIONS

Folic Acid: Allergic sensitizations have been reported following both oral and parenteral administration of folic acid.

Ferrous Fumarate: Gastrointestinal disturbances (anorexia, nausea, diarrhea, constipation, heartburn, and vomiting) occur occasionally, but are usually mild and may subside with continuation of therapy. Reducing the dose and administering it with meals will minimize these effects in the sensitive patient. Iron may turn stools black. This is a harmless effect that is a result of unabsorbed iron. Although the absorption of iron is best when taken between meals, giving Folivane™-F after meals may diminish occasional G.I disturbances. Folivane™-F is best absorbed when taken at bedtime.

OVERDOSAGE

Acute overdosage of iron may cause abdominal pain, nausea and vomiting and, in severe cases, cardiovascular collapse and death.  Other more chronic symptoms include pallor and cyanosis, melena, shock, drowsiness, and coma.  The estimated overdose of orally ingested iron is 300 mg/kg body weight.  Toxic effects are seen at 10-20 mg/kg elemental iron.  When overdoses are ingested by children, severe reactions, including fatalities, have resulted.  Folivane™-F should be stored beyond the reach of children to prevent against accidental iron poisoning.

DESCRIPTION

Folivane™-F are maroon capsules imprinted "T538" in white.

DIRECTIONS FOR USE

One (1) capsule daily, between meals, or as directed by a physician.  Do not exceed recommended dosage. 

HOW SUPPLIED

Folivane™-F is supplied in bottle of 90 capsules.
Product Code: 13811-538-90

STORAGE

Store at 20°-25°C (68°-77°F), excursion permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP with a child-resistant closure.

KEEP OUT OF REACH OF CHILDREN.

 For use on the order of a healthcare practitioner.

Call your doctor about side effects. To report side effects, call Trigen Laboratories at 1-800-444-5164 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

PLR-FOLF-00001-2     Rev. 05/2023

Manufactured for:

Trigen Laboratories, LLC

Alpharetta, GA 30005

1-770-509-4500

TRIGEN LOGO

PRINCIPAL DISPLAY PANEL - 90 Capsule Bottle Label

13811-538-90

Folivane - F
with Ascorbic Acid Precursors

IRON / FOLIC ACID / VITAMIN
SUPPLEMENT CAPSULES

90 CAPSULES

TRIGEN
LABORATORIES

Folivane-F BTL-FOF-00001-1 Rev. 01/2023
FOLIVANE-F 
ferrous fumarate, iron, folic acid, ascorbic acid, and niacin capsule
Product Information
Product TypeDIETARY SUPPLEMENTItem Code (Source)NHRIC:13811-538
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
FERROUS FUMARATE (UNII: R5L488RY0Q) (FERROUS CATION - UNII:GW89581OWR) FERROUS CATION62.5 mg
IRON (UNII: E1UOL152H7) (IRON - UNII:E1UOL152H7) IRON62.5 mg
FOLIC ACID (UNII: 935E97BOY8) (FOLIC ACID - UNII:935E97BOY8) FOLIC ACID1 mg
ASCORBIC ACID (UNII: PQ6CK8PD0R) (ASCORBIC ACID - UNII:PQ6CK8PD0R) ASCORBIC ACID40 mg
NIACIN (UNII: 2679MF687A) (NIACIN - UNII:2679MF687A) NIACIN3 mg
Inactive Ingredients
Ingredient NameStrength
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)  
HYPROMELLOSES (UNII: 3NXW29V3WO)  
MAGNESIUM STEARATE (UNII: 70097M6I30)  
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
FD&C RED NO. 40 (UNII: WZB9127XOA)  
FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)  
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NHRIC:13811-538-9090 in 1 BOTTLE, PLASTIC
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
DIETARY SUPPLEMENT01/01/2010
Supplement Facts
Serving Size : Serving per Container :
Amount Per Serving% Daily Value
color
imprint
scoring1
shape
size (solid drugs)20 mm
Labeler - Trigen Laboratories, LLC (830479668)

Revised: 5/2023
Document Id: ea314d9a-0284-4841-abe4-73ffd97d2b8a
Set id: e6e6b4c6-5d1f-4cd8-9dd5-db184b64d98e
Version: 5
Effective Time: 20230530
 
Trigen Laboratories, LLC